RIGImmune Inc.
Company Details
Status: Private
Employees: 1-10
Location:
Farmington, Connecticut, United States
Type:
sample
Technology:
sample
sample
sample
sample
About: Spun out of Yale University in 2020, RIGImmune is a platform biopharmaceutical company developing a novel investigational class of RNA immunotherapies, and advancing complimentary targeted delivery systems, for the broad-spectrum treatment of viral diseases and cancer. Led by biopharma industry veteran, President Susan Sobolov, PhD, RIGImmune’s products act to specifically modulate RIG-I, a host surveillance pathway that triggers the innate immune system to enhance the patients’ intrinsic response to disease.
RIGImmune was launched in 2020 by Yale Professors Anna Marie Pyle, PhD and Akiko Iwasaki, PhD, who are also Scientific Advisors for the company. Pyle co-discovered the RIG-I receptor family and conducted many of the first structural and biochemical investigations on RIG-I. Pyle is also a specialist in RNA structure, and design. In collaboration with Iwasaki, Pyle designed the stem loop RNAs for selective targeting of RIG-I using crystal structure data of RIG-I complexed with RNA and developed them as antitumor and anticancer compounds.
Unlock access to company contacts, hot leads, and drug pipelines.
Log in or create a free account now!
RIGImmune Inc. | Active clinical trials on ClinicalTrials.gov
Active Clinical Trials Count | 0
No Active Trials Found On ClinicalTrials.gov.